

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

180.00

Complete if Known

Application Number	10/758,335-Conf. #6410
Filing Date	January 15, 2004
First Named Inventor	Seth J. ORLOW
Examiner Name	J. D. Anderson
Art Unit	1614
Attorney Docket No.	71369.368US1/PFI-016CIPDIV

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____
 Deposit Account Deposit Account Number: 08-0219 Deposit Account Name: Wilmer Cutler Pickering Hale and Dorr LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
 Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 Credit any overpayments

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description

Each claim over 20 (including Reissues)

Fee (\$)	Small Entity
----------	--------------

50 25

Each independent claim over 3 (including Reissues)

200 100

Multiple dependent claims

360 180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims
--------------	--------------	----------	---------------	---------------------------

- 20 =	x	=		Fee (\$)	Fee Paid (\$)
--------	---	---	--	----------	---------------

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	
---------------	--------------	----------	---------------	--

- 3 =	x	=		
-------	---	---	--	--

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
--------------	--------------	--	----------	---------------

- 100 =	/50	(round up to a whole number) x	=	
---------	-----	--------------------------------	---	--

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00


SUBMITTED BY

Signature	<i>Ann-Louise Kerner</i>	Registration No. (Attorney/Agent)	33,523	Telephone	(617) 526-6000
Name (Print/Type)	Ann-Louise Kerner, Ph.D.			Date	October 6, 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 6, 2006

Signature: *Rochelle Capobianco* (Rochelle Capobianco)



10
I hereby certify that this paper (along with any paper referred to as being attached
or enclosed) is being deposited with the U.S. Postal Service on the date shown
below with sufficient postage as First Class Mail, in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450.

Dated: October 6, 2006 Signature: *Rochelle Capobianco*
(Rochelle Capobianco)

Docket No.: 0071369.00368US1
(PFI-016CIPDIV)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Seth J. ORLOW et al. Confirmation No.: 6410
Application No.: 10/758,335 Art Unit: 1614
Filed: January 15, 2004 Examiner: J. D. Anderson
Title: METHODS AND COMPOSITIONS THAT AFFECT
MELANOGENESIS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: October 6, 2006

10/12/2006 WASFAN1 00000111 080219 10758335
01 FC:1806 180.00 DA

Ann-Louise Kerner
Ann-Louise Kerner, Ph.D.
Registration No.: 33,523
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000 (telephone)
(617) 526-5000 (facsimile)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Complete if Known	
				Application Number	10/758,335-Conf. #6410
				Filing Date	January 15, 2004
				First Named Inventor	Seth J. ORLOW
				Art Unit	1614
				Examiner Name	J. D. Anderson
Sheet	1	of	2	Attorney Docket Number	0071369.00368US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA*	US-5,628,987	05-13-1997	Fuller		
AB	US-5,686,103	11-11-1997	Redziniak et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-97/00892	01-09-1997	The Government of the United States of America, represented by The Secretary Department of Health and Human Services		
	BB	WO-01/01131	01-04-2001	Univ New York		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	ABDEL-MALEK, et al., "Mitogenic, Melanogenic and cAMP Responses of Cultured Neonatal Human Melanocytes to Commonly Used Mitogens", Journal of Cellular Physiology, 150:416-425 (1992)	
	CB	ANCANS, et al., "Activation of Melanogenesis by Vacuolar Type H ⁺ -ATPase Inhibitors in Amelanotic, Tyrosinase Positive Human and Mouse Melanoma Cells", FEBS Letters, 478:57-60 (2000)	
	CC	ANSEL, et al., <u>Pharmaceutical Dosage Forms and Drug Delivery Systems</u> , Sixth Ed., A Lea & Febiger Book, Williams & Wilkins, Baltimore (1995) (cover of book and page (i))	
	CD	BOUCHARD, et al., "Induction of Pigmentation in Mouse Fibroblasts by Expression of Human Tyrosinase cDNA", J. Exp. Med., 169:2029-2042 (1989)	
	CE	BRILLIANT, et al., "Anatomy of Pigment Cell Genes Acting at the Cellular Level", in <u>The Pigmentary System: Physiology and Pathophysiology</u> , Norlund, et al., eds., Oxford University Press, Chapter 18, pp. 217-229 (1998)	
	CF	CHAKRABORTY, et al., "Effect of Arbutin on Melanogenic Proteins in Human Melanocytes", Pigment Cell Research, 11:206-212 (1998)	
	CG	GARDNER, et al., "The Complete Nucleotide Sequence of an Infectious Clone of Cauliflower Mosaic Virus by M13mp7 Shotgun Sequencing", Nucleic Acids Research, 9(12):2871-2888 (1981)	
	CH	GILBERT, et al., "Useful Proteins from Recombinant Bacteria", Sci. Am., 242(4):74-94 (1980)	
	CI	HARLOW, et al., <u>Antibodies – A Laboratory Manual</u> , Cold Spring Harbor Laboratory (1988) (cover of book and page (i))	
	CJ	HU, et al., "Regulation of Melanogenesis by Human Uveal Melanocytes In Vitro", Exp. Eye	

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/758,335-Conf. #6410
				Filing Date	January 15, 2004
				First Named Inventor	Seth J. ORLOW
				Art Unit	1614
				Examiner Name	J. D. Anderson
Sheet	2	of	2	Attorney Docket Number	0071369.00368US1
	Res., 64:397-404 (1997)				
	CK	IMOKAWA, et al., "Skin Organ Culture Model for Examining Epidermal Melanization", Journal of Investigative Dermatology, 100:47-54 (1993)			
	CL	JIMENEZ, et al., "Tyrosinases from Two Different Loci are Expressed by Normal and by Transformed Melanocytes", Journal of Biological Chemistry, 266(2):1147-1156 (1991)			
	CM	KUZUMAKI, et al., "Eumelanin Biosynthesis is Regulated by Coordinate Expression of Tyrosinase and Tyrosinase-Related Protein-1 Genes", Experimental Cell Research, 207:33-40 (1993)			
	CN	LERNER, et al., "Biochemistry of Melanin Formation", Physiol. Rev., 30(1):91-126 (1950)			
	CO	MACDONALD, "Expression of the Pancreatic Elastase I Gene in Transgenic Mice", Hepatology, 7(1):42S-51S (1987)			
	CP	MASON, et al., "The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy", Science, 234(4782):1372-1378 (1986)			
	CQ	NIEKRASZ, et al., "The Pig as Organ Donor for Man", Transplantation Proceedings, 24(2):625-626 (1992)			
	CR	OETTING, et al., "Mutations of the Human P Gene Associated with Type II Oculocutaneous Albinism (OCA2)", Human Mutation, 12(6):433-434 (1998) (abstract only)			
	CS	ORLOW, et al., "Retinoic Acid is a Potent Inhibitor of Inducible Pigmentation in Murine and Hamster Melanoma Cell Lines", Journal of Investigative Dermatology, 64(4):461-464 (1990)			
	CT	ORLOW, "The Biogenesis of Melanosomes", in <u>The Pigmentary System: Physiology and Pathophysiology</u> , Norlund, et al., eds, Oxford University Press, Chapter 6, pp. 97-106 (1998)			
	CU	ORNITZ, et al., "Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice", Cold Spring Harb. Symp. Quant. Biol., 50:399-409 (1985)			
	CV	PINKERT, et al., "An Albumin Enhancer Located 10 kb Upstream Functions Along with its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice", Genes & Development, 1:268-276 (1987)			
	CW	Product Information Sigma: Composition of the Medium MCDB-153			
	CX	Product Information Sigma: Composition of the Medium Ham's F10			
	CY	Remington's Pharmaceutical Sciences, 18th Edition, Alfonso Gennaro, Editor, Mack Publishing Company, Easton, PA (1990)			
	CZ	SAKAI, et al., "Modulation of Murine Melanocyte Function <i>in vitro</i> by Agouti Signal Protein", EMBO Journal, 16(12):3544-3552 (1997)			
	CA1	SCHWARTZ, et al., <u>Surface Active Agents, Their Chemistry and Technology</u> , Interscience Publishers, Inc, New York, NY (1949)			
	CB1	SEIBERG, et al., "Inhibition of Melanosome Transfer Results in Skin Lightening", J. Invest. Dermatol., 115:162-167 (2000)			
	CC1	SEIJI, et al., "Subcellular Localization of Melanin Biosynthesis", Annals NY Acad. Sci., 100:497-533 (1963)			
	CD1	SHANI, "Tissue-Specific Expression of Rat Myosin Light-Chain 2 Gene in Transgenic Mice", Nature, 314:283-286 (1985)			
	CE1	VIRADOR, et al., "A Standardized Protocol for Assessing Regulators of Pigmentation", Analytical Biochemistry, 270:207-219 (1999)			
	CF1	YOKOYAMA, et al., "Conserved Cysteine to Serine Mutation in Tyrosinase is Responsible for the Classical Albino Mutation in Laboratory Mice", Nucleic Acids Research, 18(24):7293-7298 (1990)			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p>					